


## **Clinical Trials Program**

Université 📩


de Montréal

Phase I clinical trial of Anti-Minor Histocompatibility Antigen Immunotherapy Broadening the Scope of Application for Precision Therapeutics

Jul. 1, 2017 to Sept. 30, 2021



minimizing the risk of GVHD. Also, they were able to develop an ex vivo immunization strategy that allows to generate T cells with anti-MiHA specificity. They will initiate a clinical trial using this novel strategy to treat patients with lymphoid HCs and also expand the HLA typing repertoire in order to increase patient reach to approximately 95% of the patient population (from the current 45% reach). MiHA-targeted immunotherapy would allow for safe, targeted and more effective treatment of patients with otherwise fatal HCs.



## BioCanR Canada's Immunotherapy Network Le réseau canadien d'immunothérapie